These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 21109967

  • 1. Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma.
    Ronkainen H, Hirvikoski P, Kauppila S, Vaarala MH.
    Oncol Rep; 2011 Jan; 25(1):129-33. PubMed ID: 21109967
    [Abstract] [Full Text] [Related]

  • 2. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC, Zincke H, Lohse CM, Sebo TJ, Riehle D, Weaver AL, Blute ML.
    Cancer; 2002 Apr 15; 94(8):2180-4. PubMed ID: 12001115
    [Abstract] [Full Text] [Related]

  • 3. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
    Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS.
    Clin Cancer Res; 2007 Dec 15; 13(24):7388-93. PubMed ID: 18094421
    [Abstract] [Full Text] [Related]

  • 4. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS.
    Cancer; 2005 Jun 15; 103(12):2517-25. PubMed ID: 15880379
    [Abstract] [Full Text] [Related]

  • 5. Prognostic significance of tenascin-C expression in clear cell renal cell carcinoma.
    Ohno Y, Izumi M, Yoshioka K, Ohori M, Yonou H, Tachibana M.
    Oncol Rep; 2008 Sep 15; 20(3):511-6. PubMed ID: 18695899
    [Abstract] [Full Text] [Related]

  • 6. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
    Phuoc NB, Ehara H, Gotoh T, Nakano M, Yokoi S, Deguchi T, Hirose Y.
    Urology; 2007 May 15; 69(5):843-8. PubMed ID: 17482919
    [Abstract] [Full Text] [Related]

  • 7. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
    Minervini A, Di Cristofano C, Gacci M, Serni S, Menicagli M, Lanciotti M, Salinitri G, Rocca CD, Lapini A, Nesi G, Bevilacqua G, Minervini R, Carini M.
    J Urol; 2008 Oct 15; 180(4):1284-9. PubMed ID: 18707725
    [Abstract] [Full Text] [Related]

  • 8. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray.
    Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Bergh A, Ljungberg B.
    Eur Urol; 2006 Dec 15; 50(6):1272-7. PubMed ID: 16814458
    [Abstract] [Full Text] [Related]

  • 9. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other.
    Tollefson MK, Thompson RH, Sheinin Y, Lohse CM, Cheville JC, Leibovich BC, Kwon ED.
    Cancer; 2007 Aug 15; 110(4):783-90. PubMed ID: 17594714
    [Abstract] [Full Text] [Related]

  • 10. Prognostic evaluation of COX-2 expression in renal cell carcinoma.
    Kankuri-Tammilehto MK, Söderström KO, Pelliniemi TT, Vahlberg T, Pyrhönen SO, Salminen EK.
    Anticancer Res; 2010 Jul 15; 30(7):3023-30. PubMed ID: 20683050
    [Abstract] [Full Text] [Related]

  • 11. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma.
    Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, Williams GH.
    Clin Cancer Res; 2005 Apr 01; 11(7):2510-7. PubMed ID: 15814627
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma.
    Yildiz E, Gokce G, Kilicarslan H, Ayan S, Goze OF, Gultekin EY.
    BJU Int; 2004 May 01; 93(7):1087-93. PubMed ID: 15142169
    [Abstract] [Full Text] [Related]

  • 13. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
    Kruck S, Merseburger AS, Hennenlotter J, Scharpf M, Eyrich C, Amend B, Sievert KD, Stenzl A, Bedke J.
    BJU Int; 2012 May 01; 109(10):1565-70. PubMed ID: 21981759
    [Abstract] [Full Text] [Related]

  • 14. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
    Lehmann J, Retz M, Nürnberg N, Schnöckel U, Raffenberg U, Krams M, Kellner U, Siemer S, Weichert-Jacobsen K, Stöckle M.
    Cancer; 2004 Oct 01; 101(7):1552-62. PubMed ID: 15378494
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma.
    Djordjevic G, Mozetic V, Mozetic DV, Licul V, Ilijas KM, Mustac E, Oguic R, Fuckar Z, Jonjic N.
    Pathol Res Pract; 2007 Oct 01; 203(2):99-106. PubMed ID: 17270362
    [Abstract] [Full Text] [Related]

  • 16. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
    Salvesen HB, Iversen OE, Akslen LA.
    Clin Cancer Res; 1998 Nov 01; 4(11):2779-85. PubMed ID: 9829742
    [Abstract] [Full Text] [Related]

  • 17. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility.
    Rodins K, Cheale M, Coleman N, Fox SB.
    Clin Cancer Res; 2002 Apr 01; 8(4):1075-81. PubMed ID: 11948116
    [Abstract] [Full Text] [Related]

  • 18. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma.
    Meyer HA, Tölle A, Jung M, Fritzsche FR, Haendler B, Kristiansen I, Gaspert A, Johannsen M, Jung K, Kristiansen G.
    Eur Urol; 2009 Mar 01; 55(3):669-78. PubMed ID: 18450365
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival.
    Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjänen K, Kosma VM.
    Br J Cancer; 1999 Aug 01; 80(12):2001-7. PubMed ID: 10471053
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.